Mariusz Burcz/Dreamstime
Pfizer Covid Vaccine Sars Cov 2 Vials Jars Assembly Fill Production Line© Mariusz Burcz Dreamstime

Pfizer Q1 Revenues Jump 77% to $25 Billion on COVID-19 Vaccine

May 3, 2022
The New York drugmaker expects just over half of this year's revenue to come from COVID vaccine and treatment sales.

Pfizer reported another quarter of huge revenues growth because of its COVID-19 vaccine on Tuesday, but lowered the company's full-year profit forecast due in part to shifts in foreign exchange.

The major American drugmaker reported revenues of $25.7 billion for the first quarter, up 77 percent from the year-ago period, with the COVID vaccine taking in $13.2 billion.

Net income jumped 61% to $7.9 billion.

Pfizer confirmed its full-year revenues forecast, in which about just over half of total sales stem from the Covid-19 inoculation and from Paxlovid, the company's therapeutic to treat the coronavirus.

Pfizer, which has shipped some 3.4 billion doses of vaccine to 179 countries, has won regulatory approval for its shot in most age groups, but continues to study its use in children younger than five.

The company is also exploring "potential next-generation vaccines, including variant vaccines" for the fall season, Chief Executive Albert Bourla said in prepared remarks.

In the first quarter, Paxlovid took in $1.5 billion in global sales. But Pfizer expects 2022 sales of the medicine of $22 billion as it ramps up production and distribution.

The World Health Organization last month "strongly recommended" the antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization. 

But WHO said it was "extremely concerned" that low- and middle-income countries would be "pushed to the end of the queue" amid tight global supplies.

Pfizer now sees full-year adjusted profits of $6.25 to $6.45 a share, down 10 cents from the previous range.

The company attributed the lowered forecast to an accounting change in research and development expenses and to changes in the foreign exchange market that have seen the dollar rise compared with other major currencies.

Shares of Pfizer dipped 1.2% to $47.77 in pre-market trading.

Copyright 2022, Agence France-Presse

Continue Reading

Popular Sponsored Recommendations

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

What Does Agility Look Like for Today's Auto Industry?

Dec. 4, 2023
Without modern technologies, enterprises aren't able to fully analyze the risks and respond to ongoing supply chain issues and semiconductor shortages.

Managing Supply Chain Risk in Aerospace and Defense!

Dec. 6, 2023
A&D companies need to adopt digital technologies that enable greater collaboration, active monitoring of leading risk indicators, & integration of supply chain risk factors into...

Beware Extreme Software

Sept. 24, 2023
As a manufacturer, you understand the importance of staying ahead of the curve and being proactive in your approach to technology. With the rapid pace of change in the industry...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!